DIM is NOT a standard or evidence-based component of testosterone therapy in women with androgen deficiency
There is no guideline-based recommendation or established clinical rationale for using diindolylmethane (DIM) alongside testosterone therapy in women with androgen deficiency. In fact, the available evidence suggests this combination could be counterproductive and potentially harmful.
Why This Combination Lacks Clinical Support
The Fundamental Problem: Opposing Mechanisms
DIM functions as an androgen antagonist and alters estrogen metabolism in ways that would theoretically work against testosterone therapy:
DIM blocks androgen receptor activity: Research demonstrates that DIM is a "strong competitive inhibitor" of dihydrotestosterone (DHT) binding to the androgen receptor and inhibits androgen receptor nuclear translocation 1. This directly opposes the intended therapeutic effect of testosterone supplementation.
DIM reduces testosterone's active metabolite: Studies show DIM down-regulates androgen receptor expression and inhibits AR phosphorylation 2, which would diminish the clinical benefits women are seeking from testosterone therapy.
Guideline Position on Testosterone in Women
The Endocrine Society's clinical practice guidelines are unequivocal about testosterone use in women:
The only evidence-based indication for testosterone in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women after formal biopsychosocial assessment 3
The guidelines recommend against generalized use of testosterone for infertility, sexual dysfunction (except HSDD), cognitive dysfunction, cardiovascular health, metabolic dysfunction, bone health, or general well-being due to inadequate indications and lack of long-term safety data 4, 5
There is no established definition of "androgen deficiency syndrome" in women because there are neither well-defined clinical syndromes nor normative testosterone data across women's lifespans 4
The Estrogen Metabolism Concern
If DIM is being recommended to "balance" estrogen metabolism during testosterone therapy, this rationale is flawed:
DIM significantly alters estrogen profiles: In postmenopausal women using transdermal estradiol, DIM supplementation caused statistically significant changes in 6 of 10 estrogen metabolites measured, including the 2-hydroxyestrone/16-hydroxyestrone ratio 6
These changes may reduce estrogenic effects: The alterations in estrogen metabolism could "decrease the overall estrogenic impact" on clinical endpoints like symptom improvement and bone mineral density 6
Testosterone can aromatize to estrogen: Since exogenous testosterone can convert to estradiol, adding DIM could interfere with this natural metabolic pathway and potentially reduce beneficial estrogenic effects
Clinical Pitfalls to Avoid
Common Misconceptions
"Androgen deficiency" is not a validated diagnosis in women: The Endocrine Society explicitly states they "recommend against making a diagnosis of androgen deficiency in women" due to lack of validated diagnostic criteria 4
Compounded "bioidentical" preparations cannot be recommended: These lack evidence for efficacy and safety, and quality control is inconsistent 3
Supraphysiologic testosterone dosing is inappropriate: Pellets and injections that result in supraphysiologic concentrations are not recommended 3
If Testosterone Therapy Is Prescribed
When testosterone is used for the single validated indication (HSDD in postmenopausal women):
- Measure baseline total testosterone before starting treatment 3
- Recheck testosterone at 3-6 weeks after initiation 3
- Monitor every 6 months for clinical response and signs of androgen excess 3
- Discontinue if no benefit by 6 months 3
- Maintain testosterone in physiologic premenopausal female range 3
- Assess for virilization signs: hirsutism, acne, male pattern balding, clitoromegaly, voice deepening 4
The Bottom Line
Adding DIM to testosterone therapy in women is not evidence-based and represents a potential drug-supplement interaction that could undermine treatment goals. DIM's anti-androgenic properties 7, 2, 1 directly contradict the therapeutic intent of testosterone supplementation.
If a provider encounters a patient taking both, they should:
- Discontinue the DIM if testosterone therapy is indicated for validated HSDD
- Reassess whether testosterone therapy is even appropriate given the restrictive evidence-based indications
- Consider that the patient may be receiving care outside evidence-based guidelines and provide appropriate counseling about risks and lack of proven benefits
The use of DIM with testosterone therapy appears to stem from non-evidence-based "functional" or "integrative" medicine practices rather than established endocrinology guidelines.